NFKB1 and gastric cancer: MUC13 overexpression has previously been described in GC and such aberrant MUC13 signaling is known to protect colorectal cancer cells from death via NF-kB pathway activation thereby impacting on therapeutic efficacy and disease outcome [12, 48].